Scholarlink

Purpose <p>To investigate the prognostic significance of pretreatment inflammatory markers and their association with computed tomography (CT)-based body composition (BC) metrics in patients with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC) treated with immunotherapy.</p> Methods <p>This retrospective, single-center study included 49 patients with HNSCC (20.4% female; median age 66 years). Eleven inflammatory markers, including the systemic-inflammatory-response-index (SIRI=(neutrophils×monocytes)/lymphocytes), derived neutrophil-to-lymphocyte ratio (dNLR=neutrophils/(leukocytes–neutrophils) were investigated. Pretreatment thoracic CTs yielded volumes of skeletal muscle (SM), visceral adipose tissue (VAT), and bone (B). Overall survival (OS) was assessed using Kaplan-Meier and Cox regression (HR: Hazard Ratio); group comparisons: Pearson’s and Mann-Whitney U.</p> Results <p>The median OS was 17.6 months. A significantly lower HR was observed in males with positive p16-status, lower ECOG, and albumin &gt; 3.4&#xa0;g/dl. Regarding inflammation, low SIRI demonstrated the strongest HR of all inflammatory markers. In multivariate analysis, low SIRI (HR: 0.17, 95% CI: 0.05–0.57, <i>p</i> = 0.0041) and low albumin (HR: 0.26, 95%CI: 0.10–0.66, <i>p</i> = 0.0047) were identified as independent prognostic factors. Correlation analysis revealed a weak association between dNLR and neutrophil/leukocyte counts with SM/B (<i>r</i>=-0.39 and − 0.47) and (SM + VAT)/B (<i>r</i> = -0.36, -0.47) (<i>p</i> ≤ 0.02). Patients with low dNLR had higher SM/B (1.77 vs. 1.35) and (SM + VAT)/B (2.05 vs. 1.54) ratios than those with high dNLR (<i>p</i> &lt; 0.0001).</p> Conclusions <p>Pretreatment SIRI and serum albumin levels are strong, independent prognostic markers for survival in HNSCC patients receiving immunotherapy. While a link between systemic inflammation, mainly driven by neutrophils, and BC-parameters has been observed, its clinical relevance warrants further investigation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Systemic inflammation plays a key prognostic role in patients with head and neck cancer treated with immunotherapy and is linked to CT-based body composition metrics

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月15日

查看全文
  • Frederic Jungbauer,
  • Sonja Ludwig,
  • Lena Huber,
  • Annette Affolter,
  • Anne Lammert,
  • Nicole Rotter,
  • Claudia Scherl,
  • Elena Seiz,
  • Farroch Vahidi Noghani,
  • Stefan O. Schönberg,
  • Johannes Haubold,
  • Clara Arndt,
  • Johannes M. Ludwig

摘要

Purpose

To investigate the prognostic significance of pretreatment inflammatory markers and their association with computed tomography (CT)-based body composition (BC) metrics in patients with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC) treated with immunotherapy.

Methods

This retrospective, single-center study included 49 patients with HNSCC (20.4% female; median age 66 years). Eleven inflammatory markers, including the systemic-inflammatory-response-index (SIRI=(neutrophils×monocytes)/lymphocytes), derived neutrophil-to-lymphocyte ratio (dNLR=neutrophils/(leukocytes–neutrophils) were investigated. Pretreatment thoracic CTs yielded volumes of skeletal muscle (SM), visceral adipose tissue (VAT), and bone (B). Overall survival (OS) was assessed using Kaplan-Meier and Cox regression (HR: Hazard Ratio); group comparisons: Pearson’s and Mann-Whitney U.

Results

The median OS was 17.6 months. A significantly lower HR was observed in males with positive p16-status, lower ECOG, and albumin > 3.4 g/dl. Regarding inflammation, low SIRI demonstrated the strongest HR of all inflammatory markers. In multivariate analysis, low SIRI (HR: 0.17, 95% CI: 0.05–0.57, p = 0.0041) and low albumin (HR: 0.26, 95%CI: 0.10–0.66, p = 0.0047) were identified as independent prognostic factors. Correlation analysis revealed a weak association between dNLR and neutrophil/leukocyte counts with SM/B (r=-0.39 and − 0.47) and (SM + VAT)/B (r = -0.36, -0.47) (p ≤ 0.02). Patients with low dNLR had higher SM/B (1.77 vs. 1.35) and (SM + VAT)/B (2.05 vs. 1.54) ratios than those with high dNLR (p < 0.0001).

Conclusions

Pretreatment SIRI and serum albumin levels are strong, independent prognostic markers for survival in HNSCC patients receiving immunotherapy. While a link between systemic inflammation, mainly driven by neutrophils, and BC-parameters has been observed, its clinical relevance warrants further investigation.